Cargando…

The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

BACKGROUND: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pantano, Francesco, Santoni, Matteo, Procopio, Giuseppe, Rizzo, Mimma, Iacovelli, Roberto, Porta, Camillo, Conti, Alessandro, Lugini, Antonio, Milella, Michele, Galli, Luca, Ortega, Cinzia, Guida, Francesco Maria, Silletta, Marianna, Schinzari, Giovanni, Verzoni, Elena, Modica, Daniela, Crucitti, Pierfilippo, Rauco, Annamaria, Felici, Alessandra, Ballatore, Valentina, Cascinu, Stefano, Tonini, Giuseppe, Carteni, Giacomo, Russo, Antonio, Santini, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401714/ https://www.ncbi.nlm.nih.gov/pubmed/25885920 http://dx.doi.org/10.1371/journal.pone.0120427

Ejemplares similares

Second-line treatment in renal cell carcinoma: clinical experience and decision making
por: Guadalupi, Valentina, et al.
Publicado: (2021)

The Synergistic Effect of Everolimus and Chloroquine on Endothelial Cell Number Reduction Is Paralleled by Increased Apoptosis and Reduced Autophagy Occurrence
por: Grimaldi, Anna, et al.
Publicado: (2013)

Pancreatitis after percutaneous ethanol injection into HCC: a minireview of the literature
por: Zardi, Enrico M, et al.
Publicado: (2008)

Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
por: Fulgenzi, Claudia Angela Maria, et al.
Publicado: (2022)

Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
por: Ballatore, Z., et al.
Publicado: (2016)

Everolimus treatment in advanced solid tumors: a personal view
por: Pusceddu, Sara, et al.
Publicado: (2015)

Feasibility of Comprehensive Genomic Profiling (CGP) in Real-Life Clinical Practice
por: Nibid, Lorenzo, et al.
Publicado: (2023)

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
por: Santini, Daniele, et al.
Publicado: (2016)

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
por: Santoni, Matteo, et al.
Publicado: (2015)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020)

New frontiers in the medical management of gastrointestinal stromal tumours
por: Mazzocca, Alessandro, et al.
Publicado: (2019)

MicroRNAs and Bone Metastasis: A New Challenge
por: Croset, Martine, et al.
Publicado: (2014)

Current and Emerging Biomarkers Predicting Bone Metastasis Development
por: Iuliani, Michele, et al.
Publicado: (2020)

Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms
por: Ribelli, Giulia, et al.
Publicado: (2021)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
por: Iuliani, Michele, et al.
Publicado: (2022)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
por: Vincenzi, Bruno, et al.
Publicado: (2012)

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
por: Buti, Sebastiano, et al.
Publicado: (2021)

Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer
por: Suriano, Francesca, et al.
Publicado: (2013)

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
por: Fioramonti, Marco, et al.
Publicado: (2017)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
por: Procopio, G, et al.
Publicado: (2012)

Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey
por: Santini, Daniele, et al.
Publicado: (2013)

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
por: Santoni, M, et al.
Publicado: (2013)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
por: Santoni, Matteo, et al.
Publicado: (2021)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Recent Advances in Desmoid Tumor Therapy
por: Napolitano, Andrea, et al.
Publicado: (2020)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Predicting Molecular Models: Where Are We Going?
por: Ratta, Raffaele, et al.
Publicado: (2015)

Functional Benefit of Smoking Cessation and Triple Inhaler in Combustible Cigarette Smokers with Severe COPD: A Retrospective Study
por: Pezzuto, Aldo, et al.
Publicado: (2022)

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
por: Verzoni, Elena, et al.
Publicado: (2019)

Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety
por: Riccardi, Ferdinando, et al.
Publicado: (2018)

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients
por: Santini, Daniele, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_aesejq8k4jie2m67qeepii1uqr